Given that CSCs confer resistance to conventional therapies, inhibiting or eliminating colorectal CSCs is necessary to effectively treat CRC and prevent recurrence; thus, ALDH1 is an attractive target for potential CRC therapies. The gene discussed is ALDH1A1; the disease is colorectal carcinoma.